APP and Alzheimer disease: Recently, administration of novel therapeutic JBPOS0101, a mGluR1 and 7 antagonist, into a 5XFAD AD mouse model demonstrated relative attenuation of memory loss and reduction in amyloid precursor protein and Aβ1–42, with authors postulating its effects being due to antagonism of primarily mGluR7, but also mild effects on mGluR1 and 5 (Park et al., 2019).